Evidence map›Paper›PMID 42008482›Full record

ArticlePloS one2026

Computational investigation of African natural products as Helicobacter pylori shikimate kinase inhibitors.

Hari Ram Sharma Paudel

Abstract read
In one paragraph

Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Hari Ram Sharma PaudelDepartment of Chemistry, Tri-Chandra Campus, Tribhuvan University, Kathmandu, Nepal.ORCID https://orcid.org/0000-0003-0815-7240

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Helicobacter pylori is one of the most prevalent bacteria, infecting more than 40% of the world's population. Rising antibiotic resistance has created an urgent need for the discovery of novel therapeutic agents. One of the potent drug targets for H. pylori is shikimic acid pathway, which synthesizes chorismate, an essential precursor for various aromatic compounds necessary for the survival of microorganisms. This pathway is absent in humans but its inhibition is lethal to microorganisms. In this study, shikimate kinase, which catalyzes the fifth step of the shikimic acid pathway, was targeted as a receptor. Potential inhibitors were sourced from the North African Natural Product Database (NANPDB) and the East African Natural Product Database (EANPDB). The natural products were investigated using computational tools. Molecular docking was used to screen the natural products and molecular dynamics simulation was used to assess the dynamic stability of docked protein-ligand complexes. The docking protocol was validated by heavy-atom superimposition of the docked shikimate 3-phosphate onto its co-crystallized conformation. Out of approximately 6500 compounds, six compounds with binding energy ranging from -8.73 to -10.57 kcal/mol were selected from molecular docking. Selected compounds showed stability during 200 ns molecular dynamics simulation. These compounds displayed strong prospects for experimental investigation of possible antibiotics against H. pylori.

Indexed as

Biological ProductsEnzyme InhibitorsHelicobacter pyloriPhosphotransferases (Alcohol Group Acceptor)AfricaLigandsMolecular Docking SimulationMolecular Dynamics SimulationShikimic AcidBiological ProductsEnzyme InhibitorsLigandsPhosphotransferases (Alcohol Group Acceptor)shikimate kinaseShikimic Acid

Identifiers

PMID42008482
PMCPMC13094947

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.